Mercado da Bronquiectasia da América do Norte – Tendências do setor e previsão para 2028

Personalize o seu relatório Personalize o seu relatório Comprar agora Comprar agora Relatório de amostra grátis Relatório de amostra grátis
Casa Pharmaceutical North America Bronchiectasis Market
Pedido de resumo Pedido de TOC Fale com Analista Fale com o analista Comprar agora Comprar agora Consulte antes Comprar Consulte antes Relatório de amostra grátis Relatório de amostra grátis

Mercado da Bronquiectasia da América do Norte – Tendências do setor e previsão para 2028

  • Pharmaceutical
  • Publish Reports
  • Sep 2021
  • North America
  • 350 Páginas
  • Número de tabelas: 119
  • Número de figuras: 50
Comprar agora Comprar agora

>Mercado de bronquiectasia da América do Norte, por tipo de doença (bronquiectasia CF e bronquiectasia não-FC), gravidade (leve a moderada e moderada a grave), tipo (diagnóstico e tratamento), tipo de medicamento (de marca e genéricos ), via de administração ( Oral, parentérica e inalatória), utilizador final (hospitais, clínicas, assistência médica domiciliária e outros), canal de distribuição (farmácia hospitalar, farmácia de retalho , farmácia on-line, outros), país (EUA, Canadá, México), tendências e previsões da indústria 2021 a 2028.

Mercado da Bronquiectasia da América do Norte

Análise e insights de mercado : Mercado de bronquiectasia da América do Norte

O mercado norte-americano de bronquiectasia deverá ganhar crescimento de mercado no período de previsão de 2021 a 2028. A Data Bridge Market Research analisa que o mercado está a crescer com um CAGR de 6,1% no período de previsão de 2021 a 2028 e prevê-se que atinja os 396,93.

A bronquiectasia compreende características que a necessidade crescente de produtos seguros e eficazes terá impacto no lançamento de novas criações dos fabricantes no mercado que aumentam a sua procura, bem como o aumento do investimento em investigação e desenvolvimento leva ao crescimento do mercado. Estão actualmente a ser realizados vários estudos de investigação que deverão criar uma vantagem competitiva para os fabricantes desenvolverem produtos novos e inovadores para a bronquiectasia, o que deverá proporcionar várias outras oportunidades no mercado da bronquiectasia. No entanto, as complicações no tratamento das bronquiectasias e os desafios de diagnóstico deverão restringir o crescimento do mercado no período de previsão.

O relatório de mercado da Bronquiectasia fornece detalhes da quota de mercado, novos desenvolvimentos e análise do pipeline de produtos, impacto dos participantes do mercado doméstico e localizado, analisa as oportunidades em termos de bolsas de receitas emergentes, alterações nas regulamentações do mercado , aprovações de produtos , decisões estratégicas, lançamentos de produtos, geografia expansões e inovações tecnológicas no mercado. Para compreender a análise e o cenário do mercado contacte-nos para um resumo do analista, a nossa equipa irá ajudá-lo a criar uma solução de impacto na receita para atingir o objetivo desejado.

Mercado da Bronquiectasia da América do NorteÂmbito e dimensão do mercado de bronquiectasia da América do Norte

O mercado da bronquiectasia está segmentado com base no tipo de doença, gravidade, tipo, tipo de medicamento, via de administração, utilizador final e canal de distribuição O crescimento entre segmentos ajuda a analisar nichos de crescimento e estratégias para abordar o mercado e determinar as suas principais áreas de aplicação e a diferença nos seus mercados-alvo.

  • On the basis of disease type, the bronchiectasis market is segmented into CF bronchiectasis and non-CF bronchiectasis. In 2021, non-CF bronchiectasis is expected to dominate the bronchiectasis market as it is highly prevalent form of bronchiectasis with higher cases reported among women and older population. 
  • On the basis of severity, the North America bronchiectasis market is segmented into mild to moderate and moderate-to-severe. In 2021, mild to moderate segment is expected to dominate the bronchiectasis market because on initiation of bronchiectasis patients experiences mild cough, airway blockage among others which sustain for life time. 
  • On the basis of type, the bronchiectasis market is segmented into diagnosis and treatment. In 2021, treatment segment is expected to dominate the bronchiectasis market because bronchiectasis is a life- long chronic disease. Severity of disease increase with increasing age and hence affected population relies on effective treatment approaches.
  • On the basis of drugs type, the bronchiectasis market is segmented into branded and generics. In 2021, branded segment is expected to dominate the bronchiectasis market because products offered by the many companies are the patent formulation and rising patient certitude towards branded formulations.
  • On the basis of route of administration, the bronchiectasis market is segmented into oral, parenteral, and inhalation. In 2021, inhalation segment is expected to dominate the bronchiectasis market because on high efficacy rate of inhalation drug formulation for treatment of respiratory disease. Moreover increasing innovation for development of smart inhalers equipped with drug dosage regulation is another factor boosting the market growth.
  • On the basis of end user, the bronchiectasis market is segmented into hospitals, clinics, home healthcare, and others. In 2021, hospitals segment is dominating the bronchiectasis market because most of the patients suffering from bronchiectasis visit hospitals in order to achieve accurate disease diagnosis and to experience effective treatment under the specialized professionals.
  • On the basis of distribution channel, the bronchiectasis market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy and others. In 2021, hospital pharmacy is expected to dominate the bronchiectasis market as hospital pharmacy offers wide ranges of drugs, therapies along with proper consultation and brand awareness.

Mercado da Bronquiectasia da América do NorteBronchiectasis Market Country Level Analysis

The bronchiectasis market is analyzed and market size information is provided on the basis of disease type, severity, type, drugs type, route of administration, end user and distribution channel.

The countries covered in the bronchiectasis market report are the U.S., Canada, Mexico.

Mild to moderate segment in North America region is expected to grow with the highest growth rate in the forecast period of 2021 to 2028 because of increasing clinical trials and research development for prevention of respiratory diseases among the adults. U.S. is leading the growth of the North America market and Mild to moderate segment is dominating in this country because Bronchiectasis is a chronic, progressive and recurrent pulmonary infections these symptoms causes severe issues in patient day to day life. So, these symptoms seen in the initial stage of the bronchiectasis and treatment can be done on initial stage. Canada is expected to grow in the market due to rising government initiatives for treatment of rare diseases moreover Mexico is attaining lucrative growth due to rising cases of respiratory diseases and increase in awareness towards the better treatment options.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Rising Awareness for Prevention of Bronchiectasis and Increasing Healthcare Expenditure are Boosting the Market Growth of Bronchiectasis

Bronchiectasis market also provides you with detailed market analysis for every country growth in Bronchiectasis industry with Bronchiectasis drugs sales, impact of advancement in the Bronchiectasis technology and changes in regulatory scenarios with their support for the Bronchiectasis market. The data is available for historic period 2010 to 2019.

Competitive Landscape and Bronchiectasis Market Share Analysis

Bronchiectasis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to Bronchiectasis market.

As principais empresas que lidam com a bronquiectasia são a Abbott, HERSILL, Home Oxygen Company, Inogen, Inc., Boehringer Ingelheim International GmbH, Medline Industries, Inc, Ache Laboratories Farmaceuticos SA, Horizon Therapeutics plc, Janssen Pharmaceuticals, Inc. da Johnson & Johnson Services , Inc.), Trudell Medical International, GlaxoSmithKline plc., AstraZeneca, Pfizer Inc., Merck Sharp & Dohme Corp., uma subsidiária da Merck & Co., Inc., Novartis AG, Teva Pharmaceutical USA Inc. (uma subsidiária da Teva Pharmaceutical Industries Ltd.), Sun Pharmaceutical Industries Ltd., Bayer AG, Dr. Reddy’s Laboratories Ltd., Sunovion Pharmaceuticals Inc. (uma subsidiária da Zydus Cadila), Cipla Inc., Electromed, Inc., entre outras.

Muitos lançamentos e acordos de produtos são também iniciados pelas empresas de todo o mundo que também estão a acelerar o mercado das bronquiectasias.

Por exemplo,

  • Em junho de 2019, a AstraZeneca recebeu aprovação para o Breztri Aerosphere (PT010), composto por budesonida/glicopirrónio/fumarato de formoterol no Japão. O produto é amplamente utilizado no tratamento de inflamações associadas aos pulmões. Esta aprovação permitiu à empresa obter vendas constantes e aumentar o volume de negócios da empresa.
  • Em março de 2019, a Novartis AG lançou o Ultibro Breezhaler e o Seebri Breezhaler (inaladores para a DPOC), que se mostraram eficazes no tratamento de doenças respiratórias inflamatórias e infeciosas. Esta iniciativa impulsionou o portefólio de produtos da empresa e permitiu expandir a sua presença no mercado das bronquiectasias.

A colaboração, o lançamento de produtos, a expansão do negócio, a atribuição de prémios e reconhecimento, as joint ventures e outras estratégias do player de mercado estão a melhorar o mercado da empresa no mercado da Bronquiectasia, o que também oferece o benefício para a organização melhorar a sua oferta para a Bronquiectasia.

SKU-

Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo

Sample Image Click on image to enlarge
  • Painel interativo de análise de dados
  • Painel de análise da empresa para oportunidades de elevado potencial de crescimento
  • Acesso de analista de pesquisa para personalização e customização. consultas
  • Análise da concorrência com painel interativo
  • Últimas notícias, atualizações e atualizações Análise de tendências
  • Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Pedido de demonstração

Índice

  1. introduction
    1. OBJECTIVES OF THE STUDY
    2. MARKET DEFINITION
    3. OVERVIEW of North America bronchiectasis market
    4. LIMITATIONs
    5. MARKETS COVERED
  2. MARKET SEGMENTATION
    1. MARKETS COVERED
    2. geographical scope
    3. years considered for the study
    4. currency and pricing
    5. DBMR TRIPOD DATA VALIDATION MODEL
    6. MULTIVARIATE MODELLING
    7. disease type LIFELINE CURVE
    8. primary interviews with key opinion leaders
    9. DBMR MARKET POSITION GRID
    10. vendor share analysis
    11. MARKET drugs type COVERAGE GRID
    12. secondary sourcEs
    13. assumptions
  3. EXECUTIVE SUMMARY
  4. premium insight
  5. Pipeline analysis
  6. North America bronchiectasis market: Laws and regulations
  7. Epidemiology
  8. Market Overview
    1. Drivers
      1. Rising Patient Population Suffering from bronchiectasis
      2. growing geriatric population
      3. rising number of smokers and consumption of alcohol
      4. technological advancement for disease testing
      5. growing DIAGNOSTIC rate
    2. restrainTs
      1. high cost of diagnostic tools
      2. product recalls
      3. inappropriate reimbursement policies
    3. opportunities
      1. Rising awareness for prevention of bronchiectasis in primary and secondary care
      2. increasing healthcare expenditure
      3. increase in research regarding the bronchiectasis disease
    4. challenges
      1. complications in the treatment of bronchiectasis
      2. lack of skilled professionals
      3. diagnositic challenges
  9. IMPACT OF COVID-19
    1. PRICE IMPACT
    2. IMPACT ON DEMAND
    3. IMPACT ON SUPPLY CHAIN
    4. STRATEGIC DECISIONS FOR MANUFACTURERS
    5. CONCLUSION
  10. North America bronchiectasis market, BY disease type
    1. overview
    2. Non-CF Bronchiectasis
    3. CF Bronchiectasis
  11. North America bronchiectasis market, BY severity
    1. overview
    2. mild to moderate
    3. moderate to severe
  12. North America bronchiectasis market, BY type
    1. overview
    2. treatment
      1. Antibiotics
        1. MACROLIDE
          1. AZITHROMYCIN
          2. CLARITHROMYCIN
          3. OTHERS
        2. AMOXICILLIN
        3. CEPHALOSPORIN
          1. SECOND-GENERATION CEPHALOSPORIN
          2. THIRD-GENERATION CEPHALOSPORIN
        4. AMINOGLYCOSIDE
          1. GENTAMICIN
          2. TOBRAMYCIN
        5. FLUOROQUINOLONE
        6. TETRACYCLINS
        7. TRIMETHOPRIM-SULFAMETHOXAZOLE
        8. COMBINATION THERAPY
      2. Corticosteroids
        1. BUDESONIDE
        2. FLUTICASONE
        3. MOMETASONE
        4. FLUNISOLIDE
        5. OTHERS
      3. Bronchodilators
        1. LONG-ACTING BRONCHODILATORS
          1. FORMOTEROL
          2. TIOTROPIUM
          3. SALMETEROL
          4. OTHERS
        2. SHORT-ACTING BRONCHODILATORS
          1. ALBUTEROL
          2. LEVALBUTEROL
          3. OTHERS
      4. Mucus Thinning Medicine
        1. CARBOCISTEINE
        2. BROMHEXINE
        3. OTHERS
      5. Airway Clearance Devices
        1. OSCILLATING POSITIVE EXPIRATORY PRESSURE (PEP)
        2. INTRAPULMONARY PERCUSSIVE VENTILATION (IPV)
        3. POSTURAL DRAINAGE
        4. OTHERS
      6. Oxygen Therapy
        1. OXYGEN CONCENTRATORS
        2. COMPRESSED GAS OXYGEN
        3. LIQUID OXYGEN
      7. Surgery
        1. BRONCHOSCOPY
        2. LUNG TRANSPLANT
      8. Others
    3. diagnosis
      1. Chest CT Scan
      2. Sputum Test
      3. Pulmonary Function Test
      4. X-Ray
      5. Others
  13. North America bronchiectasis market, BY drugs type
    1. overview
    2. branded
    3. generics
  14. North America bronchiectasis market, BY route of administration
    1. overview
    2. inhalation
    3. oral
      1. Tablets
      2. Capsules
      3. Others
    4. parenteral
      1. Intravenous
      2. Subcutaneous
      3. Others
  15. North America bronchiectasis market, BY end user
    1. overview
    2. hospitals
    3. clinics
    4. home healthcare
    5. others
  16. North America bronchiectasis market, BY distribution channel
    1. overview
    2. Hospital Pharmacy
    3. retail Pharmacy
    4. online pharmacy
    5. others
  17. North America bronchiectasis market by region
    1. NORTH AMERICA
      1. U.S.
      2. CANADA
      3. MEXICO
  18. North America bronchiectasis market: COMPANY landscape
    1. company share analysis: north america
  19. SWOT
  20. Company profiles
    1. AstraZeneca
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    2. GlaxoSmithKline plc.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    3. Teva Pharmaceutical USA Inc. (A Subsidiary of Teva Pharmaceutical Industries Ltd.)
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    4. Merck Sharp & Dohme Corp. (A subsidiary of Merck & Co., Inc.)
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    5. Novartis AG
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    6. abbott
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENT
    7. Ache Laboratories Farmaceuticos S.A.
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    8. Bayer AG
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    9. boehringer ingelheim international gmbh
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENT
    10. Cipla Inc.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    11. Dr. Reddy’s Laboratories Ltd.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    12. Electromed, Inc.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    13. hersill
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    14. home oxygen company
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENT
    15. horizon therapeutics plc
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENT
    16. inogen, inc.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    17. Janssen Pharmaceuticals, Inc. (A Subsidiary of Johnson & Johnson Services, Inc.)
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENT
    18. medline industries, inc.
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    19. Pfizer Inc.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    20. Sunovion Pharmaceuticals Inc. (A Subsidiary of Sumitomo Dainippon Pharma Co., Ltd.)
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    21. Sun Pharmaceutical Industries Ltd.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    22. truedell medical international
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    23. Viatris Inc.
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    24. Zydus Pharmaceuticals, Inc. (A subsidiary of Zydus Cadila)
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
  21. questionnaire
  22. related reports

Lista de Tabela

TABLE 1 North America bronchiectasis market, pipeline analysis

TABLE 2 REGULATION imposed by several regulatory agencies in different regions

TABLE 3 Healthcare expenditure in north america per capita (usd)

TABLE 4 THE PRICE OF X-RAY MACHINE

TABLE 5 North America bronchiectasis market, By Disease Type, 2019-2028 (USD Million)

TABLE 6 North America bronchiectasis market, By Severity, 2019-2028 (USD Million)

TABLE 7 North America bronchiectasis market, By Type, 2019-2028 (USD Million)

TABLE 8 north america Treatment by Antibiotics in Bronchiectasis Market, By Type, 2019-2028 (USD Million)

TABLE 9 north america Treatment by Macrolide Antibiotics in Bronchiectasis Market, By Type, 2019-2028 (USD Million)

TABLE 10 north america Treatment by Cephalosporin Antibiotics in Bronchiectasis Market, By Type, 2019-2028 (USD Million)

TABLE 11 north america Treatment by Aminoglycoside Antibiotics in Bronchiectasis Market, By Type, 2019-2028 (USD Million)

TABLE 12 north america Treatment by Corticosteroids in Bronchiectasis Market, By Type, 2019-2028 (USD Million)

TABLE 13 north america Treatment by Bronchodilators in Bronchiectasis Market, By Type, 2019-2028 (USD Million)

TABLE 14 north america Treatment by Long-Acting Bronchodilators in Bronchiectasis Market, By Type, 2019-2028 (USD Million)

TABLE 15 north america Treatment by Short-Acting Bronchodilators in Bronchiectasis Market, By Type, 2019-2028 (USD Million)

TABLE 16 north america Treatment by Mucus Thinning Medicine in Bronchiectasis Market, By Type, 2019-2028 (USD Million)

TABLE 17 north america Treatment by Airway Clearance Devices in Bronchiectasis Market, By Type, 2019-2028 (USD Million)

TABLE 18 north america Treatment by Oxygen Therapy in Bronchiectasis Market, By Type, 2019-2028 (USD Million)

TABLE 19 north america Treatment by Surgery in Bronchiectasis Market, By Type, 2019-2028 (USD Million)

TABLE 20 north america Diagnosis in Bronchiectasis Market, By Type, 2019-2028 (USD Million)

TABLE 21 North America bronchiectasis market, By Drugs Type, 2019-2028 (USD Million)

TABLE 22 North America bronchiectasis market, By Route of Administration, 2019-2028 (USD Million)

TABLE 23 north america Oral Administration in Bronchiectasis Market, By Route of Administration, 2019-2028 (USD Million)

TABLE 24 north america Parenteral Administration in Bronchiectasis Market, By Route of Administration, 2019-2028 (USD Million)

TABLE 25 North America bronchiectasis market, By End User, 2019-2028 (USD Million)

TABLE 26 North America bronchiectasis market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 27 NORTH AMERICA BRONCHIECTASIS MARKET, BY COUNTRY, 2018-2028 (USD MILLION)

TABLE 28 NORTH America BRONCHIECTASIS Market, By disease type, 2019-2028 (USD Million)

TABLE 29 NORTH America BRONCHIECTASIS Market, By severity, 2019-2028 (Usd million)

TABLE 30 NORTH America BRONCHIECTASIS Market, By type, 2019-2028 (USD Million)

TABLE 31 NORTH America treatment in BRONCHIECTASIS Market, By type, 2019-2028 (USD Million)

TABLE 32 NORTH America treatment by antibiotics in BRONCHIECTASIS Market, By type, 2019-2028 (USD Million)

TABLE 33 North America Treatment by Macrolide Antibiotics in Bronchiectasis Market, By Type, 2019-2028 (USD Million)

TABLE 34 North America Treatment by Cephalosporin Antibiotics in Bronchiectasis Market, By Type, 2019-2028 (USD Million)

TABLE 35 North America Treatment by Aminoglycoside Antibiotics in Bronchiectasis Market, By Type, 2019-2028 (USD Million)

TABLE 36 North America Treatment by Corticosteroids in Bronchiectasis Market, By Type, 2019-2028 (USD Million)

TABLE 37 North America Treatment by Bronchodilators in Bronchiectasis Market, By Type, 2019-2028 (USD Million)

TABLE 38 North America Treatment by Long-Acting Bronchodilators in Bronchiectasis Market, By Type, 2019-2028 (USD Million)

TABLE 39 North America Treatment by Short-Acting Bronchodilators in Bronchiectasis Market, By Type, 2019-2028 (USD Million)

TABLE 40 North America Treatment by Mucus Thinning Medicine in Bronchiectasis Market, By Type, 2019-2028 (USD Million)

TABLE 41 North America Treatment by Airway Clearance Devices in Bronchiectasis Market, By Type, 2019-2028 (USD Million)

TABLE 42 North America Treatment by Oxygen Therapy in Bronchiectasis Market, By Type, 2019-2028 (USD Million)

TABLE 43 North America Treatment by Surgery in Bronchiectasis Market, By Type, 2019-2028 (USD Million)

TABLE 44 North America Diagnosis in Bronchiectasis Market, By Type, 2019-2028 (USD Million)

TABLE 45 North America Bronchiectasis Market, By Drugs Type, 2019-2028 (USD Million)

TABLE 46 North America Bronchiectasis Market, By Route of Administration, 2019-2028 (USD Million)

TABLE 47 North America Oral Administration in Bronchiectasis Market, By Route of Administration, 2019-2028 (USD Million)

TABLE 48 North America Parenteral Administration in Bronchiectasis Market, By Route of Administration, 2019-2028 (USD Million)

TABLE 49 NORTH America BRONCHIECTASIS Market, By end usernel, 2019-2028 (USD Million)

TABLE 50 NORTH America BRONCHIECTASIS Market, By distribution channel, 2019-2028 (USD Million)

TABLE 51 U.S. BRONCHIECTASIS Market, By disease type, 2019-2028 (USD Million)

TABLE 52 U.S. BRONCHIECTASIS Market, By severity, 2019-2028 (Usd million)

TABLE 53 U.S. BRONCHIECTASIS Market, By type, 2019-2028 (USD Million)

TABLE 54 U.S. treatment in BRONCHIECTASIS Market, By type, 2019-2028 (USD Million)

TABLE 55 U.S. treatment by antibiotics in BRONCHIECTASIS Market, By type, 2019-2028 (USD Million)

TABLE 56 U.s. Treatment by Macrolide Antibiotics in Bronchiectasis Market, By Type, 2019-2028 (USD Million)

TABLE 57 U.S. Treatment by Cephalosporin Antibiotics in Bronchiectasis Market, By Type, 2019-2028 (USD Million)

TABLE 58 u.S. Treatment by Aminoglycoside Antibiotics in Bronchiectasis Market, By Type, 2019-2028 (USD Million)

TABLE 59 u.s. Treatment by Corticosteroids in Bronchiectasis Market, By Type, 2019-2028 (USD Million)

TABLE 60 u.s. Treatment by Bronchodilators in Bronchiectasis Market, By Type, 2019-2028 (USD Million)

TABLE 61 u.s. Treatment by Long-Acting Bronchodilators in Bronchiectasis Market, By Type, 2019-2028 (USD Million)

TABLE 62 u.s. Treatment by Short-Acting Bronchodilators in Bronchiectasis Market, By Type, 2019-2028 (USD Million)

TABLE 63 u.s. Treatment by Mucus Thinning Medicine in Bronchiectasis Market, By Type, 2019-2028 (USD Million)

TABLE 64 u.s. Treatment by Airway Clearance Devices in Bronchiectasis Market, By Type, 2019-2028 (USD Million)

TABLE 65 u.s. Treatment by Oxygen Therapy in Bronchiectasis Market, By Type, 2019-2028 (USD Million)

TABLE 66 u.s. Treatment by Surgery in Bronchiectasis Market, By Type, 2019-2028 (USD Million)

TABLE 67 u.s. Diagnosis in Bronchiectasis Market, By Type, 2019-2028 (USD Million)

TABLE 68 u.s. Bronchiectasis Market, By Drugs Type, 2019-2028 (USD Million)

TABLE 69 u.s. Bronchiectasis Market, By Route of Administration, 2019-2028 (USD Million)

TABLE 70 u.s. Oral Administration in Bronchiectasis Market, By Route of Administration, 2019-2028 (USD Million)

TABLE 71 u.s. Parenteral Administration in Bronchiectasis Market, By Route of Administration, 2019-2028 (USD Million)

TABLE 72 u.s. BRONCHIECTASIS Market, By end usernel, 2019-2028 (USD Million)

TABLE 73 u.s. BRONCHIECTASIS Market, By distribution channel, 2019-2028 (USD Million)

TABLE 74 canada BRONCHIECTASIS Market, By disease type, 2019-2028 (USD Million)

TABLE 75 canada BRONCHIECTASIS Market, By severity, 2019-2028 (Usd million)

TABLE 76 canada BRONCHIECTASIS Market, By type, 2019-2028 (USD Million)

TABLE 77 canada treatment in BRONCHIECTASIS Market, By type, 2019-2028 (USD Million)

TABLE 78 canada treatment by antibiotics in BRONCHIECTASIS Market, By type, 2019-2028 (USD Million)

TABLE 79 canada Treatment by Macrolide Antibiotics in Bronchiectasis Market, By Type, 2019-2028 (USD Million)

TABLE 80 canada Treatment by Cephalosporin Antibiotics in Bronchiectasis Market, By Type, 2019-2028 (USD Million)

TABLE 81 canada Treatment by Aminoglycoside Antibiotics in Bronchiectasis Market, By Type, 2019-2028 (USD Million)

TABLE 82 canada Treatment by Corticosteroids in Bronchiectasis Market, By Type, 2019-2028 (USD Million)

TABLE 83 canada Treatment by Bronchodilators in Bronchiectasis Market, By Type, 2019-2028 (USD Million)

TABLE 84 canada Treatment by Long-Acting Bronchodilators in Bronchiectasis Market, By Type, 2019-2028 (USD Million)

TABLE 85 canada Treatment by Short-Acting Bronchodilators in Bronchiectasis Market, By Type, 2019-2028 (USD Million)

TABLE 86 canada Treatment by Mucus Thinning Medicine in Bronchiectasis Market, By Type, 2019-2028 (USD Million)

TABLE 87 canada Treatment by Airway Clearance Devices in Bronchiectasis Market, By Type, 2019-2028 (USD Million)

TABLE 88 canada Treatment by Oxygen Therapy in Bronchiectasis Market, By Type, 2019-2028 (USD Million)

TABLE 89 canada Treatment by Surgery in Bronchiectasis Market, By Type, 2019-2028 (USD Million)

TABLE 90 canada Diagnosis in Bronchiectasis Market, By Type, 2019-2028 (USD Million)

TABLE 91 canada Bronchiectasis Market, By Drugs Type, 2019-2028 (USD Million)

TABLE 92 canada Bronchiectasis Market, By Route of Administration, 2019-2028 (USD Million)

TABLE 93 canada Oral Administration in Bronchiectasis Market, By Route of Administration, 2019-2028 (USD Million)

TABLE 94 canada Parenteral Administration in Bronchiectasis Market, By Route of Administration, 2019-2028 (USD Million)

TABLE 95 canada BRONCHIECTASIS Market, By end user, 2019-2028 (USD Million)

TABLE 96 canada BRONCHIECTASIS Market, By distribution channel, 2019-2028 (USD Million)

TABLE 97 mexico BRONCHIECTASIS Market, By disease type, 2019-2028 (USD Million)

TABLE 98 mexico BRONCHIECTASIS Market, By severity, 2019-2028 (Usd million)

TABLE 99 mexico BRONCHIECTASIS Market, By type, 2019-2028 (USD Million)

TABLE 100 mexico treatment in BRONCHIECTASIS Market, By type, 2019-2028 (USD Million)

TABLE 101 mexico treatment by antibiotics in BRONCHIECTASIS Market, By type, 2019-2028 (USD Million)

TABLE 102 mexico Treatment by Macrolide Antibiotics in Bronchiectasis Market, By Type, 2019-2028 (USD Million)

TABLE 103 mexico Treatment by Cephalosporin Antibiotics in Bronchiectasis Market, By Type, 2019-2028 (USD Million)

TABLE 104 mexico Treatment by Aminoglycoside Antibiotics in Bronchiectasis Market, By Type, 2019-2028 (USD Million)

TABLE 105 mexico Treatment by Corticosteroids in Bronchiectasis Market, By Type, 2019-2028 (USD Million)

TABLE 106 mexico Treatment by Bronchodilators in Bronchiectasis Market, By Type, 2019-2028 (USD Million)

TABLE 107 mexico Treatment by Long-Acting Bronchodilators in Bronchiectasis Market, By Type, 2019-2028 (USD Million)

TABLE 108 mexico Treatment by Short-Acting Bronchodilators in Bronchiectasis Market, By Type, 2019-2028 (USD Million)

TABLE 109 mexico Treatment by Mucus Thinning Medicine in Bronchiectasis Market, By Type, 2019-2028 (USD Million)

TABLE 110 mexico Treatment by Airway Clearance Devices in Bronchiectasis Market, By Type, 2019-2028 (USD Million)

TABLE 111 mexico Treatment by Oxygen Therapy in Bronchiectasis Market, By Type, 2019-2028 (USD Million)

TABLE 112 mexico Treatment by Surgery in Bronchiectasis Market, By Type, 2019-2028 (USD Million)

TABLE 113 mexico Diagnosis in Bronchiectasis Market, By Type, 2019-2028 (USD Million)

TABLE 114 mexico Bronchiectasis Market, By Drugs Type, 2019-2028 (USD Million)

TABLE 115 mexico Bronchiectasis Market, By Route of Administration, 2019-2028 (USD Million)

TABLE 116 mexico Oral Administration in Bronchiectasis Market, By Route of Administration, 2019-2028 (USD Million)

TABLE 117 mexico Parenteral Administration in Bronchiectasis Market, By Route of Administration, 2019-2028 (USD Million)

TABLE 118 mexico BRONCHIECTASIS Market, By end usernel, 2019-2028 (USD Million)

TABLE 119 mexico BRONCHIECTASIS Market, By distribution channel, 2019-2028 (USD Million)

Lista de Figura

FIGURE 1 North America bronchiectasis market: SEGMENTATION

FIGURE 2 NORTH AMERICA BRONCHIECTASIS MARKET : DATA TRIANGULATION

FIGURE 3 North America bronchiectasis market: DROC ANALYSIS

FIGURE 4 North America bronchiectasis market: Global VS REGIONAL MARKET ANALYSIS

FIGURE 5 North America bronchiectasis market: COMPANY RESEARCH ANALYSIS

FIGURE 6 North America bronchiectasis market: MULTIVARIATE MODELLING

FIGURE 7 North America bronchiectasis market: INTERVIEW DEMOGRAPHICS

FIGURE 8 NORTH AMERICA BRONCHIECTASIS MARKET: DBMR MARKET POSITION GRID

FIGURE 9 NORTH AMERICA BRONCHIECTASIS MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 North America bronchiectasis market: MARKET drugs type COVERAGE GRID

FIGURE 11 North America bronchiectasis market: SEGMENTATION

FIGURE 12 RISING PATIENT POPULATION SUFFERING FROM BRONCHIECTASIS is DRIVing THE North America bronchiectasis market IN THE FORECAST PERIOD OF 2021 to 2028

FIGURE 13 NON-CF BRONCHIECTASIS SEGMENT is expected to account for the largest share of the North America bronchiectasis market in 2021 & 2028

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGEs OF North America bronchiectasis market

FIGURE 15 Number of Persons Aged 60 Years Across Several Regions in 2017 and 2050

FIGURE 16 Health Spending by Major Sources of Funds

FIGURE 17 North America bronchiectasis market: BY disease type, 2021

FIGURE 18 North America bronchiectasis market: BY disease type, 2019-2028 (USD Million)

FIGURE 19 North America bronchiectasis market: BY disease type, CAGR (2021-2028)

FIGURE 20 North America bronchiectasis market: BY disease type, LIFELINE CURVE

FIGURE 21 North America bronchiectasis market: BY severity, 2021

FIGURE 22 North America bronchiectasis market: BY severity, 2019-2028 (USD Million)

FIGURE 23 North America bronchiectasis market: BY severity, CAGR(2021-2028)

FIGURE 24 North America bronchiectasis market: BY severity, LIFELINE CURVE

FIGURE 25 North America bronchiectasis market: BY type, 2021

FIGURE 26 North America bronchiectasis market: BY type, 2019-2028 (USD Million)

FIGURE 27 North America bronchiectasis market: BY type, CAGR (2021-2028)

FIGURE 28 North America bronchiectasis market: BY type, LIFELINE CURVE

FIGURE 29 North America bronchiectasis market: BY drugs type, 2021

FIGURE 30 North America bronchiectasis market: BY drugs type, 2019-2028 (USD Million)

FIGURE 31 North America bronchiectasis market: BY drugs type, CAGR (2021-2028)

FIGURE 32 North America bronchiectasis market: BY drugs type, LIFELINE CURVE

FIGURE 33 North America bronchiectasis market: BY route of administration, 2021

FIGURE 34 North America bronchiectasis market: BY route of administration, 2019-2028 (USD Million)

FIGURE 35 North America bronchiectasis market: BY route of administration, CAGR (2021-2028)

FIGURE 36 North America bronchiectasis market: BY route of administration, LIFELINE CURVE

FIGURE 37 North America bronchiectasis market: BY end user, 2021

FIGURE 38 North America bronchiectasis market: BY end user, 2019-2028 (USD Million)

FIGURE 39 North America bronchiectasis market: BY end user, CAGR (2021-2028)

FIGURE 40 North America bronchiectasis market: BY end user, LIFELINE CURVE

FIGURE 41 North America bronchiectasis market: BY distribution channel, 2021

FIGURE 42 North America bronchiectasis market: BY distribution channel, 2019-2028 (USD Million)

FIGURE 43 North America bronchiectasis market: BY distribution channel, CAGR (2021-2028)

FIGURE 44 North America bronchiectasis market: BY distribution channel, LIFELINE CURVE

FIGURE 45 NORTH America BRONCHIECTASIS market: SNAPSHOT (2020)

FIGURE 46 NORTH America BRONCHIECTASIS market: BY COUNTRY (2020)

FIGURE 47 NORTH America BRONCHIECTASIS market: BY COUNTRY (2021 & 2028)

FIGURE 48 NORTH America BRONCHIECTASIS market: BY COUNTRY (2020 & 2028)

FIGURE 49 NORTH America BRONCHIECTASIS market: BY disease type (2021-2028)

FIGURE 50 North America Bronchiectasis Market: company share 2020 (%)

View Detailed Information Right Arrow

Metodologia de Investigação

A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados ​​e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.

A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis ​​de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.

Personalização disponível

A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.

Navegue pelas páginas relacionadas

Banner